Enveda Biosciences raises $311 million in Series E

Enveda's approach starts with nature: its AI identifies molecules in plants and microbes, predicts their structure and function, and ranks them by drug potential. Its chemists then turn the most promising ones into drug prospects — a pipeline that CEO and founder Viswa Colluru said in June was already evaluating 17 programs. That research has now produced three drugs in human testing. ENV-294, a pill for atopic dermatitis, showed potential to reduce eczema symptoms in a small early trial and could help people who don't respond to approved treatments like Dupixent, with Phase 2 trials underway in eczema and asthma. ENV-308 mimics a hormone the body releases after exercise or meals and is being tested for maintaining weight loss after stopping GLP-1 use. A third, ENV-6949, targets the TL1A pathway for inflammatory bowel disease.

The funding itself is notable for its size — $311 million rivals totals secured in some of the biotechnology sector's larger IPOs this year. Enveda had previously banked more than $530 million in venture backing, including a $150 million Series D in 2025. This latest round was led by Catalio Capital Management and includes 16 other backers, among them Surveyor Capital, T. Rowe Price, Lux Capital and a sovereign wealth fund.

Colluru has described the strategy as putting multiple drugs into the clinic and partnering each when its value inflection is right, so the company gets both validation and capital to move other candidates forward. How well that works may depend on whether Enveda's clinical results confirm the promise its AI-guided discovery process has suggested.